Previously, I wrote about Paxlovid being underprescribed for treating acute Covid in patients at high risk for serious illness. The FDA granted an Emergency Use Authorization based on data showing that “Paxlovid significantly reduced the proportion of people with Covid-19 related hospitalization or death” by 88% compared to placebo.

In unvaccinated people, Paxlovid was also associated with a 26% lower risk of long Covid in a study by Ziyad Al-Aly.

The data on Paxlovid for those previously vaccinated is mixed. A smaller study from the University of California at San Francisco found no benefit in people who had been previously vaccinated.